Immunic (NASDAQ:IMUX) Earns Buy Rating from D. Boral Capital

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $17.00 target price on the stock.

Several other research analysts have also recently issued reports on IMUX. StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Immunic in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $12.67.

Immunic Price Performance

Shares of NASDAQ IMUX opened at $1.15 on Wednesday. The business’s 50 day moving average is $1.03 and its two-hundred day moving average is $1.25. The stock has a market capitalization of $103.59 million, a P/E ratio of -0.93 and a beta of 1.87. Immunic has a 1-year low of $0.92 and a 1-year high of $2.11.

Hedge Funds Weigh In On Immunic

Large investors have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after purchasing an additional 42,383 shares in the last quarter. State Street Corp raised its holdings in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after buying an additional 11,642 shares during the period. Jane Street Group LLC boosted its position in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. Virtu Financial LLC acquired a new stake in shares of Immunic in the third quarter valued at $50,000. Finally, HB Wealth Management LLC acquired a new position in Immunic in the 4th quarter valued at about $81,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.